Idiopathic pulmonary fibrosis is a progressive form of fibrosing interstitial pneumonia with a fatal prognosis and a significant impact on the quality of life of affected patients.

Nintedanib was shown to be effective in reducing the decline in lung function of patients with idiopathic pulmonary fibrosis and was approved for treatment of idiopathic pulmonary fibrosis less than 3 years ago.

New studies indicate that nintedanib effectively slows disease progression up to 3 years, and is efficacious in mild, moderate and severe stages of the disease.

Nintedanib is well tolerated and safe up to 3 years, with diarrhoea being the most common adverse event.